Equitiesbullish2 min read
Antengene Licenses ATG-106 to K2 for $20M | $6996.HK $XBI
Antengene licenses ATG-106 to K2 Therapeutics in a deal worth up to $20M, securing non-dilutive funding. Read the full financial and sector analysis.
Market Snapshot
XBI
Current Price
--
--
Last updated: -- BRT
Analyst Consensus
Executive dispatch: analyst consensus for $XBI is mixed, with no dominant conviction across the latest related wires.
Related Tickers
Antengene licenses ATG-106 to K2 Therapeutics in a deal worth up to $20M, securing non-dilutive funding. Read the full financial and sector analysis.